Reviewing MariMed (OTCMKTS:MRMD) and Maravai LifeSciences (NASDAQ:MRVI)

MariMed (OTCMKTS:MRMD) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares MariMed and Maravai LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-7.82%	-5.00%	-1.29%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MariMed and Maravai LifeSciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	2	0	0	2.00
Maravai LifeSciences	2	0	3	0	2.20

Maravai LifeSciences has a consensus price target of $5.50, indicating a potential upside of 13.64%. Given Maravai LifeSciences’ stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than MariMed.

Insider and Institutional Ownership

0.2% of MariMed shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 17.3% of MariMed shares are owned by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MariMed and Maravai LifeSciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MariMed	$159.83 million	0.19	-$14.48 million	($0.03)	-2.55
Maravai LifeSciences	$185.74 million	6.73	-$130.77 million	($0.71)	-6.82

MariMed has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than MariMed, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

MariMed has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.

Summary

MariMed beats Maravai LifeSciences on 8 of the 14 factors compared between the two stocks.

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.